Advanced search
Add to list

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Vander Cruyssen, Bert, et al. “Four-Year Follow-up of Infliximab Therapy in Rheumatoid Arthritis Patients with Long-Standing Refractory Disease: Attrition and Long-Term Evolution of Disease Activity.” ARTHRITIS RESEARCH & THERAPY, vol. 8, no. 4, BIOMED CENTRAL LTD, 2006.
APA
Vander Cruyssen, B., Van Looy, S., Wyns, B., WESTHOVENS, R., DUREZ, P., Van den Bosch, F., … De Keyser, F. (2006). Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. ARTHRITIS RESEARCH & THERAPY, 8(4).
Chicago author-date
Vander Cruyssen, Bert, Stijn Van Looy, Bart Wyns, R WESTHOVENS, P DUREZ, Filip Van den Bosch, Herman Mielants, et al. 2006. “Four-Year Follow-up of Infliximab Therapy in Rheumatoid Arthritis Patients with Long-Standing Refractory Disease: Attrition and Long-Term Evolution of Disease Activity.” ARTHRITIS RESEARCH & THERAPY 8 (4).
Chicago author-date (all authors)
Vander Cruyssen, Bert, Stijn Van Looy, Bart Wyns, R WESTHOVENS, P DUREZ, Filip Van den Bosch, Herman Mielants, L DE CLERCK, A PERETZ, M MALAISE, L VERBRUGGEN, N VASTESAEGER, A GELDHOF, Luc Boullart, and Filip De Keyser. 2006. “Four-Year Follow-up of Infliximab Therapy in Rheumatoid Arthritis Patients with Long-Standing Refractory Disease: Attrition and Long-Term Evolution of Disease Activity.” ARTHRITIS RESEARCH & THERAPY 8 (4).
Vancouver
1.
Vander Cruyssen B, Van Looy S, Wyns B, WESTHOVENS R, DUREZ P, Van den Bosch F, et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. ARTHRITIS RESEARCH & THERAPY. 2006;8(4).
IEEE
[1]
B. Vander Cruyssen et al., “Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity,” ARTHRITIS RESEARCH & THERAPY, vol. 8, no. 4, 2006.
@article{413330,
  author       = {{Vander Cruyssen, Bert and Van Looy, Stijn and Wyns, Bart and WESTHOVENS, R and DUREZ, P and Van den Bosch, Filip and Mielants, Herman and DE CLERCK, L and PERETZ, A and MALAISE, M and VERBRUGGEN, L and VASTESAEGER, N and GELDHOF, A and Boullart, Luc and De Keyser, Filip}},
  issn         = {{1478-6362}},
  journal      = {{ARTHRITIS RESEARCH & THERAPY}},
  language     = {{eng}},
  number       = {{4}},
  publisher    = {{BIOMED CENTRAL LTD}},
  title        = {{Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity}},
  volume       = {{8}},
  year         = {{2006}},
}

Web of Science
Times cited: